Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial.
Autorzy:
SchubertML; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Schmitt A; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Hückelhoven-Krauss A; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Neuber B; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Kunz A; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Waldhoff P; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Vonficht D; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. Yousefian S; Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany. Jopp-Saile L; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. Wang L; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Korell F; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Keib A; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Michels B; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Haas D; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Sauer T; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Derigs P; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Kulozik A; Department of Pediatric Hematology, Oncology and Immunology, University Hospital Heidelberg, Heidelberg, Germany. Kunz J; Department of Pediatric Hematology, Oncology and Immunology, University Hospital Heidelberg, Heidelberg, Germany. Pavel P; Institute for Clinical Transfusion Medicine and Cell Therapy (IKTZ), German Red Cross Blood Service Baden-Württemberg-Hessen, Heidelberg, Germany. Laier S; Institute for Clinical Transfusion Medicine and Cell Therapy (IKTZ), German Red Cross Blood Service Baden-Württemberg-Hessen, Heidelberg, Germany. Wuchter P; Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, of the Heidelberg University, German Red Cross Blood Service Baden-Württemberg - Hessen, Mannheim, Germany. Schmier J; GRN MVZ Sinsheim, Sinsheim, Germany. Bug G; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany. Lang F; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany. Gökbuget N; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany. Casper J; Department of Hematology and Oncology, University Hospital Oldenburg, Oldenburg, Germany. Görner M; Department of Hematology and Oncology, Hospital Bielefeld, Bielefeld, Germany. Finke J; Department of Internal Medicine I, University Hospital Freiburg, Freiburg, Germany. Neubauer A; Department of Hematology, Oncology and Immunology, University Hospital Giessen und Marburg, Marburg, Germany. Ringhoffer M; Städtisches Klinikum Karlsruhe, Karlsruhe, Germany. Wolleschak D; Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany. Brüggemann M; Department of Internal Medicine II, University Hospital Kiel, Kiel, Germany. Haas S; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.; Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), Heidelberg, Germany. Ho AD; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), Heidelberg, Germany. Müller-Tidow C; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), Heidelberg, Germany. Dreger P; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), Heidelberg, Germany. Schmitt M; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. .; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), Heidelberg, Germany. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2023 Jul 22; Vol. 16 (1), pp. 79. Date of Electronic Publication: 2023 Jul 22.
Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR.
Autorzy:
Schanda N; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Sauer T; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Kunz A; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Hückelhoven-Krauss A; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Neuber B; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Wang L; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Hinkelbein M; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Sedloev D; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. He B; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. SchubertML; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Müller-Tidow C; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Schmitt M; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Schmitt A; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Pokaż więcej
Źródło:
Cells [Cells] 2021 Nov 17; Vol. 10 (11). Date of Electronic Publication: 2021 Nov 17.
Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma.
Autorzy:
Korell F; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. SchubertML; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Sauer T; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Schmitt A; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Derigs P; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Weber TF; Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Schnitzler P; Department of Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Müller-Tidow C; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Dreger P; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Schmitt M; Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Apr 02; Vol. 13 (7). Date of Electronic Publication: 2021 Apr 02.
Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells.
Autorzy:
Gong W; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Department of Hematology, First Affiliated Hospital of Soochow University, Suzhou 215006, China. Wang L; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. Stock S; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. Ni M; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550025, China. SchubertML; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. Neuber B; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. Kleist C; Department of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany. Hückelhoven-Krauss A; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. Wu D; Department of Hematology, First Affiliated Hospital of Soochow University, Suzhou 215006, China. Müller-Tidow C; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany. Schmitt A; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. Shiku H; Department of Immuno-Gene Therapy, Mie University, Tsu 514-8507, Japan. Schmitt M; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany.; National Center for Tumor Diseases (NCT), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany. Sellner L; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Takeda Pharma Vertrieb GmbH & Co. KG, 10117 Berlin, Germany.
Pokaż więcej
Źródło:
Cells [Cells] 2021 Jan 14; Vol. 10 (1). Date of Electronic Publication: 2021 Jan 14.
Typ publikacji:
Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR.
Autorzy:
SchubertML; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. Kunz A; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. Schmitt A; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. Neuber B; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. Wang L; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. Hückelhoven-Krauss A; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. Langner S; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. Michels B; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. Wick A; Department of Neurology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Daniel V; Department of Immunology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Müller-Tidow C; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany. Dreger P; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany. Schmitt M; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2020 Sep 30; Vol. 12 (10). Date of Electronic Publication: 2020 Sep 30.
Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
Autorzy:
Korell F; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany. Laier S; Institute of Clinical Transfusion Medicine and Cell Therapy (IKTZ), 89081 Heidelberg, Germany. Sauer S; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany. Veelken K; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany. Hennemann H; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany. SchubertML; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany. Sauer T; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany. Pavel P; Institute of Clinical Transfusion Medicine and Cell Therapy (IKTZ), 89081 Heidelberg, Germany. Mueller-Tidow C; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany. Dreger P; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany. Schmitt M; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany. Schmitt A; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Pokaż więcej
Źródło:
Cells [Cells] 2020 May 15; Vol. 9 (5). Date of Electronic Publication: 2020 May 15.
Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.
Autorzy:
Yoo HJ; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. hyeonjoo_. Liu Y; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. . Wang L; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. . SchubertML; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. Maria-Luisa.Schubert@med.uni-heidelberg.de. Hoffmann JM; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. . Wang S; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. . Neuber B; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. . Hückelhoven-Krauss A; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. . Gern U; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. . Schmitt A; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. . Müller-Tidow C; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. .; National Center for Tumor Diseases (NCT), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany. . Dreger P; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. .; National Center for Tumor Diseases (NCT), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany. . Mokhir A; Organic Chemistry II, Department Chemistry and Pharmacy, Friedrich-Alexander-University of Erlangen-Nürnberg, 91058 Erlangen, Germany. . Schmitt M; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. .; National Center for Tumor Diseases (NCT), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany. . Sellner L; Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany. .; National Center for Tumor Diseases (NCT), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany. .
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML).
Autorzy:
Hofmann S; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. . SchubertML; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. Maria-Luisa.Schubert@med.uni-heidelberg.de. Wang L; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. . He B; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. . Neuber B; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. . Dreger P; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. .; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany. . Müller-Tidow C; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. .; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany. . Schmitt M; Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany. .; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany. .
Performance characteristics of optical coherence tomography in assessment of Barrett's esophagus and esophageal cancer: systematic review.
Autorzy:
Kohli DR; Division of Gastroenterology, Virginia Commonwealth University Health System and Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA. SchubertML; Division of Gastroenterology, Virginia Commonwealth University Health System and Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA. Zfass AM; Division of Gastroenterology, Virginia Commonwealth University Health System and Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA. Shah TU; Division of Gastroenterology, Virginia Commonwealth University Health System and Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
